COULD WE IDENTIFY PRIMARY HEADACHE AS GLUTAMATE?


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The data on the pathogenesis of primary headaches (PHB) is presented. It is hypothesized that PHB is formed in patients exposed to it, expressed differing genetically determined reaction of various neuronal systems in the «normal» or a more serious stress. Since many mental disorders are formed by the same mechanisms, the patient can be observed as PHB and mental disorder. The data that the greatest contribution to the occurrence of PHB makes increased activity of the glutamate system. As a result PHB is characterized by rapid conducting pain impulses, the phenomenon of inflation, excitotoxicity, violations of attention and efficiency, decreased libido and some symptoms of depression. It is assumed, that PHB must be treated with drugs that reduce the activity of the glutamate system (in particular, flupirtine).

全文:

受限制的访问

作者简介

Mikhail Drobizhev

I.M. Sechenov First Moscow State Medical University; Research and Clinical Center «Healthy heart»

Email: dmyu2001@mail.ru
MD, Leading Researcher 119435, Moscow, 6/1 B. Pirogovskaya St

Anastasiya Fedotova

N.I. Pirogov Russian National Research Medical University

PhD, Associate Professor, Department of neurology

Sergey Kikta

Polyclinic № 3 of Department for Presidential Affairs of the Russian Federation

PhD, Head of Department of psychotherapy, psychiatry, narcology

参考

  1. Вознесенская Т.Г. Головные боли напряжения. http://medi.ru/doc/8381004.htm
  2. Сергеев А.В. Головная боль напряжения: современное состояние проблемы. РМЖ. 2014;22:1573-81
  3. Дробижев М.Ю., Федотова А.В., Кикта С.В. Патогенетическая фармакотерапия фобических тревожных расстройств и состояний, обусловленных стрессом. Профилактическая медицина. 2013;4:34-9.
  4. Stahl S.M. Stahl's essential psychopharmacology: neuroscientific basis and practical application. 3 nd ed. Cambridge University Press, 2008. 11 17 p.
  5. Международная классификация болезней, 10-й пересмотр. http://мкб-10.рф
  6. Shin H.E., Han S.J., Lee K.S., Park J.W. Polymorphism of the glutamate transporter protein EAAT2 and migraine transformation into chronic daily headache. J. Clin. Neurol. 2011;7(3):143-7.
  7. Gallai V., Alberti A., Gallai B., Coppola F., Floridi A., Sarchielli P. Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia. 2003;23(3):166-74.
  8. Curto M., Lionetto L., Negro A., Capi M., Perugino F., Fazio F., Giamberardino M.A., Simmaco M., Nicoletti F., Martelletti P. Altered serum levels of kynurenine metabolites in patients affected by cluster headache. J. Headache Pain. 2015;17(1):27.
  9. Амелин А.В., Игнатов Ю.Д., Скоромец А.А., Соколов А.Ю. Мигрень. Патогенез, клиника, фармакотерапия: руководство для врачей. 3-е изд. М.: МЕДпресс-информ, 2014. 256 с.
  10. Садоха К.А., Головко Т.Г. Роль серотонина в патогенезе и лечении мигрени. Медицинские новости. 2005;4:15-6
  11. Park H.K., Lee S.Y., Kim S.E., Yun C.H., Kim S.H. Small deep white matter lesions are associated with right-to-left shunts in migraineurs. J. Neurol. 2011;258(3):427-33.
  12. Borkum J.M. Migraine triggers and oxidative stress: A narrative review and synthesis. Headache. 2016;56(1):12-35.
  13. Rossom R., Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am. J. Geriatr. Pharmacother. 2004;2(4):303-12.
  14. Riva D., Usilla A., Aggio F., Vago C., Treccani C., Bulgheroni S. Attention in children and adolescents with headache. Headache. 2012;52(3):374-84.
  15. Henry M.E., Jensen J.E., Licata S.C., Ravichandran C., Butman M.L., Shanahan M., Lauriat T.L., Renshaw P.F. The acute and late CNS glutamine response to benzodiazepine challenge: a pilot pharmacokinetic study using proton magnetic resonance spectroscopy. Psychiatry Res. 2010;184(3):171-6.
  16. Nappi R.E., Terreno E., Tassorelli C., Sances G., Allena M., Guaschino E., Antonaci F., Albani F., Polatti F. Sexual function and distress in women treated for primary headaches in a tertiary university center. J. Sex Med. 2012;9(3):761-9.
  17. Harish S., Bhuvana K., Bengalorkar G.M., Kumar T.N. Flupirtine: Clinical pharmacology. J. Anaesthesiol. Clin. Pharmacol. 2012;28(2):172-7.
  18. Баринов А.Н. Механизмы хронизации боли, феномен взвинчивания («wind up»). http://www.paininfo.ru/events/ vein10/reports/3388.html
  19. Jakob R., Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones. Br. J. Pharmacol. 1997;122:1333-8.
  20. Nickel B., Jakovlev V., Szelenyi I. Effects of flupirtine, some analgesics and muscle relaxants on skeletal muscle tone in conscious rats. Arzneimittelforschung. 1990;40:909-11.
  21. Zimmer G., Balakirev M., Hofmann M., Woodcock B.G., Pergande G. Evidence that the cytoprotective action of the triaminopyridine flupirtine involves increases in Ca2+ uptake and ATP synthesis in mitochondria. Br. J. Pharmacol. 1998;123:1154-8.
  22. Devulder J. Flupirtine in pain management pharmacological properties and clinical use. CNS Drugs. 2010;24:867-81.
  23. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness: results of a postmarket surveillance study. Fortschr. Med. Orig. 2003;121:11-8.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##